# Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

> **NCT05372614** · PHASE1 · SUSPENDED · sponsor: **National Cancer Institute (NCI)** · enrollment: 33 (actual)

## Conditions studied

- Metastatic Malignant Solid Neoplasm
- Unresectable Malignant Solid Neoplasm

## Interventions

- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Echocardiography Test
- **PROCEDURE:** Multigated Acquisition Scan
- **DRUG:** Neratinib Maleate
- **BIOLOGICAL:** Trastuzumab Deruxtecan

## Key facts

- **NCT ID:** NCT05372614
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-10-05
- **Primary completion:** 2025-09-17
- **Final completion:** 2027-01-23
- **Target enrollment:** 33 (ACTUAL)
- **Why stopped:** Other - Correlative sample analysis.
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05372614

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05372614, "Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT05372614. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*